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Oncogenic osteomalacia is a rare metabolic bone disease characterized by hypophosphatemia, renal phosphate wasting, 
suppressed 1,25-dihydroxyvitamin D production, and osteomalacia. A phosphaturic factor secreted by these tumors is 
responsible for the symptomatology. The main mechanism underlying this disease condition is an over expression of 
fibroblast growth factor 23 (FGF-23). Complete excision of these tumors facilitates successful reversal of the problem. 
We report the case of a patient who was crippled and on extensive investigation revealed an oncogenic osteomalacia 
with tumor focus in right tibia. The tumor was identified as a mesenchymal tumor, i.e. hemangiopericytoma. Tumor 
excision alleviated patient symptoms with rapid symptomatic and biochemical improvement.
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Introduction
Tumors responsible for oncogenic osteomalacia are 
usually benign but generalized; debilitating osteo-
malacia and rickets are important clinical problems 
for the patient. The main mechanism underlying 
this disease condition is a circulating phosphaturic 
factor called phosphatonin, which is infact a Fibro-
blast growth factor 23 (FGF-23) intricately involved 
in phosphate homeostasis and skeletogenesis. It 
is a 30-kDa secreted protein processed by a pro-
convertase type enzyme into an amino and a car-
boxy fragment. This factor inhibits renal tubular 
reabsorption of phosphate and renal conversion of 
25-hydroxyvitamin D to 1,25-dihydroxyvitamin D. 
FGF-23 levels are increased in some, but not in all 
patients with osteogenic osteomalacia.
FGF-23 produces muscle weakness, bone pain, and 
osteomalacia due to markedly reduced serum phos-
phorus and renal phosphate. When serum phosphate 
concentration is less than 0.3 mmol/L, symptoms be-
come apparent.1 The most frequent underlying ab-
normality is severe 25-OH vitamin D (25-D) deficiency 
with secondary hyperparathyroidism and parathy-
roid hormone (PTH)-dependent renal phosphate loss. 
Serum calcium and PTH levels are normal and 
1,25-dihydroxyvitamin D is low in these cases.
Oncogenic osteomalacia is usually caused by be-
nign mesenchymal tumors, such as hemangioperi-
cytomas, fibromas, or giant cell tumors, often of the 
skeletal extremities or skull. It has also been de-
scribed in sarcomas and in patients with prostate 
and lung cancer. Resection of the tumor reverses 
the disorder, confirming its humoral basis.
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Brief History
A 56-year-old male presented with progressive lower 
limb weakness and inability to walk with general-
ized body pains. Magnetic resonance imaging (MRI) 
reported lumbar canal stenosis. Patient gradually 
became wheel chair bound with severe body aches 
for more than 3 years. As his MRI brain was normal, 
tropical spastic paraparesis was suspected. He later 
presented to our hospital where he was thoroughly 
evaluated.
Results
Biochemically serum alkaline phosphatase was raised 
in presence of normal serum calcium, PTH, reduced 
vitamin D3 and serum phosphorus. Urinary calcium 
excretion (24-hour) was normal but with hyperphos-
phaturia. Venous sampling was used to confirm local 
FGF-23 production and was found to be 389 kRU/L 
(normal range: 5−210 kRU/L). X-ray pelvis suggested 
severe osteoporosis while a whole body 99mTc meth-
ylene diphosphate skeletal scintigraphy showed 
features of metabolic bone disease (Figure 1).
Based on this a diagnosis of hypophosphatemic 
osteomalacia was made and patient was started on 
oral phosphate replacement. On trying to evaluate 
causes of hypophosphaturia a provisional diagnosis 
of tumor induced osteomalacia was also thought.
In this line, a whole body 99mTc red blood cell 
(RBC) blood pool scintigraphy was performed as a 
screening procedure and an abnormal focus of RBC 
accumulation was found in right tibia (Figure 2). 
An MRI of lower limb further confirmed the above 
finding (Figure 3). He underwent a complete tumor 
excision and histopathology was reported to be hem-
angiopericytoma (Figure 4). Postoperatively there 
was a dramatic improvement in general condition 
(started walking within 6 weeks) and his serum phos-
phorous became normal. A repeat bone scan also 
showed resolution of many previously reported 
hotspots.
Discussion
Tumor-induced osteomalacia is typically caused by 
benign mesenchymal tumors of vascular or skeletal 
origin, comprising of pericytes.2 Stout and Murray3 
first described the tumor in 1942 in the lungs but it 
can occur anywhere in the body. The tumor has been 
reported to occur in the extremities, pelvis,4 head 
and neck,5 back, retroperitoneum and abdomen.6 
Primary central nervous system occurrence has also 
been reported.7 Manifestation in bone is extremely 
rare but has been reported in a foot bone.
Current consensus using the World Health 
Organization classification of soft tissue tumors 
discourages use of haemangiopericytoma as a pri-
mary diagnosis because they are derived from fibro-
blasts, rather than pericytes as initially proposed.7 
Weidner and Santa Cruz8 classified this heterogene-
ous group of tumors into four types: phosphaturic 
mesenchymal tumor, mixed connective tissue type, 
osteoblastoma-like tumors; ossifying fibrous-like 
tumors; and nonossifying fibrous-like tumors. Hem-
angiopericytoma is described as one of the most 
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Figure 1 99mTc-methylene diphosphate whole body bone scan (dual intensity) showing multiple hot spots in bilateral 
ribs, sternum, periarticular increased tracer uptake in large joints—features consistent with metabolic bone disease.






Figure 2 (A) Whole body 99mTc red blood cell (RBC) blood 
pool scintigraphy (dual intensity) and (B) lower limb static 
image. Scan was performed with 20 mCi 99mTc in vivo 
labelled RBC. An abnormal focus of labeled RBC accumu-
lation was seen in lower third shaft of right tibia.
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Figure 3 Magnetic resonance imaging of both lower 
limbs showed two elongated tumors corresponding to 
the site of focal red blood cell accumulation in right 
tibial shaft.
Figure 4 Histopathology of right tibial tumor—phospha-
turic mesenchymal tumor showing round to oval, spindle 
shaped cells in a vascular background having a hemangio-
pericytoma like pattern. Presence of myxoid matrix around 
vascular channels and multinucleated giant cells.
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frequent appearing neoplasms associated with tumor 
induced osteomalacia.
Three possible mechanisms of FGF-23 over ex-
pression can be postulated in these patients lead-
ing to their characteristic presentations.6 First, 
increased levels of FGF-23 leads to renal tubular 
dysfunction and skeletal effects as occurred in our 
patient. The second plausible explanations after 
doing genetic studies have been linked to specific 
mutations of arginine residues at position 176 or 
179 of FGF-23 which disrupt the sequence motif 
recognized by furin proteases, presumably leading 
to alterations in processing or decreased degrada-
tion of the protein—the mechanism of disease being 
autosomal dominant hypophosphatemic rickets. The 
next cause may be the loss of function of PHEX 
(phosphate-regulating gene with homologies to en-
dopeptidases on the X chromosome), which occurs 
in X-linked hypophosphatemia, results in increased 
circulating levels of FGF-23.
Pathophysiology associated with overexpression 
of FGF-23 by these tumors is decreased resorption 
of phosphate in the renal tubules leading to hypo-
phosphatemia and hyperphosphaturia. Chronic hypo-
phosphatemia causes abnormal mineralization of 
bone, increased alkaline phosphatase and osteo-
malacia. Localization and resection of the FGF-23-
secreting tumor offers the best chance of cure. 
The final diagnosis in our patient is phosphaturic 
mesenchymal tumor of right tibia, i.e. hemangio-
pericytoma induced osteomalacia with vitamin D 
deficiency.
Conclusion
We learn the following points from our case:
1. Occult vascular bone lesions can be conveniently 
screened with either a whole body bone scan or 
more precisely with Tc-labeled RBC blood pool 
scan in patients with high clinical suspicion 
with very less radiation exposure to patient.
2. Oncogenic osteomalacia presents as a tetrad of 
very low serum phosphate level, increased uri-
nary phosphate excretion, inappropriately low 
to low-normal 1,25-dihydroxyvitamin D levels, 
and elevated serum FGF-23.
3. Increased FGF-23 is a useful tumor marker in 
identification of these tumors as evident in our 
case.
4. Many tumors are small and asymptomatic, exten-
sive imaging studies may be required to identify 
the source. Tc-MDP whole body bone scan and 
RBC-labeled scintigraphy are useful, noninvasive, 
economical, whole body screening investigation, 
which can be used in any age group to identify 
occult vascular tumors.
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